融合伙伴的故事系列丨无意苦争春,一任群芳妒:FGFR融合基因融合谱的故事
参考文献
[1] Babina I S, Turner N C. Advances andchallenges in targeting FGFR signalling in cancer [J]. Nat Rev Cancer, 2017, 17(5):318-332.
[2] Katoh M. Therapeutics Targeting FGFSignaling Network in Human Diseases [J]. Trends Pharmacol Sci, 2016, 37(12):1081-1096.
[3] Perez-Moreno P, Brambilla E, Thomas R, et al. Squamous cell carcinoma of thelung: molecular subtypes and therapeutic opportunities [J]. Clin Cancer Res,2012, 18(9): 2443-2451.
[4] Brooks AN, Kilgour E, Smith PD.Molecular pathways: fibroblast growth factor signaling: a new therapeuticopportunity in cancer [J]. ClinCancer Res, 2012, 18(7): 1855-1862.
[5] Singh D, ChanJ M, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma[J]. Science, 2012, 337(6099): 1231-1235.
[6] Parker B C,Annala M J, Cogdell D E, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma [J]. JClin Invest, 2013, 123(2): 8558-8565.
[7] Arai Y,Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define aunique molecular subtype of cholangiocarcinoma [J]. Hepatology, 2014, 59(4):1427-1434.
[8] Wu Y M, Su F,Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers[J]. Cancer Discov,2013, 3(6): 636-647.
[9] ZehirA, Benayed R, Shah R H, et al. Mutational landscape of metastatic cancer revealed from prospectiveclinical sequencing of 10,000 patients [J]. Nat Med, 2017, 23(6):703-313.
[10] Qin A, Johnson A, Ross J S, et al. Detection of Known and Novel FGFRFusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling [J]. JThorac Oncol, 2019,14(1): 54-62.
[11] Ang C. Role of the fibroblast growthfactor receptor axis in cholangiocarcinoma [J]. J Gastroenterol Hepatol, 2015,30(7): 1116-1122.
[12] BoradM J, Champion M D, Egan J B, et al. Integratedgenomic characterization reveals novel, therapeutically relevant drug targets inFGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma [J]. PLoSGenet, 2014,10(2): e1004135.
[13] Ross J S, Wang K, Gay L, et al. Newroutes to targeted therapy of intrahepatic cholangiocarcinomas revealed bynext- generation sequencing[J]. Oncologist, 2014, 19(3): 235- 242.
[14] SiaD, Losic B, Moeini A, et al. Massiveparallel sequencing uncovers actionable FGFR2- PPHLN1 fusion and ARAF mutationsin intrahepatic cholangiocarcinoma[J]. Nat Commun, 2015, 6: 6087.
[15] Arai Y,Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define aunique molecular subtype of cholangiocarcinoma [J]. Hepatology, 2014, 59(4):1427- 1434.
[16] Wang Y, DingX, Wang S, et al. Antitumor effect ofFGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mousemodel endogenously expressing an FGFR2-CCDC6 fusion protein [J]. Cancer Lett, 2016, 380(1): 163-73.
[17] Linzey J R, MariniB, McFadden K, et al. Identificationand targeting of an FGFR fusion in a pediatric thalamic "centraloligodendroglioma" [J]. NPJ Precis Oncol, 2017, 1(1): 29.
[18] Granberg KJ, Annala M, Lehtinen B, et al. Strong FGFR3 staining is a marker for FGFR3 fusions in diffusegliomas [J]. Neuro Oncol, 2017,19(9): 1206-1216.
[19] VandekerkhoveG, Todenhofer T, Annala M, et al. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genomeof Metastatic Bladder Cancer [J]. Clin Cancer Res, 2017, 23(21): 6487-6497.
[20] Nakanishi Y,Akiyama N, Tsukaguchi T, et al. Mechanism of Oncogenic Signal Activation by the Novel Fusion KinaseFGFR3-BAIAP2L1 [J]. MolCancer Ther, 2015, 14(3): 704-12.